Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
14 Apr 2008 Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies
14 Apr 2008 Immunomedics Reports Veltuzumab Enhances Radioimmunotherapy With Epratuzumab in Lymphoma Model
14 Apr 2008 Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
14 Apr 2008 PDL BioPharma Announces Data Presentations for Antibody Pipeline Products
14 Apr 2008 Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
14 Apr 2008 Cell Genesys Reports Preclinical Data Demonstrating Superior Anti-Tumor Immunity for Multiantigen Compared to Single-Antigen Immunotherapies
14 Apr 2008 Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
13 Apr 2008 U3 Pharma achieves preclinical proof of concept for U3-1287 (AMG 888)
10 Apr 2008 Glenmark completes preclinical development for initiating Phase I trials for GBR 500 – a monoclonal antibody for inflammation
09 Apr 2008 Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
09 Apr 2008 Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment
09 Apr 2008 Seattle Genetics Highlights SGN-70 at AAI Annual Meeting
09 Apr 2008 CuraGen Advances CR011-vcMMAE into Phase II
08 Apr 2008 ACZ885, a new biological drug in development, shows potential in treating serious life-long autoinflammatory diseases
08 Apr 2008 Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
08 Apr 2008 Amgen Statement on Romiplostim PDUFA Date
08 Apr 2008 U.S. Food and Drug Administration Approves ORENCIA(R) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
03 Apr 2008 Medarex Announces Ipilimumab Program Continues to Move Forward
02 Apr 2008 Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
01 Apr 2008 Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma
31 Mar 2008 Phase II results for CDP791 in non-small cell lung cancer support further clinical development
31 Mar 2008 Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
28 Mar 2008 Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial
27 Mar 2008 Thallion provides update on Shigamabs (R) program
27 Mar 2008 Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
26 Mar 2008 DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Novel Antibody Therapies
20 Mar 2008 Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
20 Mar 2008 CHMP Upholds Negative Opinion for the EU Application for Cimzia® in the Treatment of Crohn's Disease
20 Mar 2008 Seattle Genetics Initiates SGN-33 Clinical Trial in Combination with Revlimid(R) for Myelodysplastic Syndromes (MDS)
20 Mar 2008 Zevalin(R) Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment
19 Mar 2008 MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
18 Mar 2008 Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
17 Mar 2008 Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
17 Mar 2008 MorphoSys Obtains Agreement for Production of Antibody Material in MOR202 Program with Crucell and DSM
16 Mar 2008 GlaxoSmithKline's Bosatria shows promise in late-stage study
13 Mar 2008 Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
12 Mar 2008 BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies
12 Mar 2008 Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
11 Mar 2008 Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10 Mar 2008 iCo Therapeutics Provides iCo-008 Phase II Clinical Update
05 Mar 2008 Phase I/II Studies of IMC-A12 in Pediatric Cancer Patients Commence Enrollment
05 Mar 2008 Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
04 Mar 2008 UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
04 Mar 2008 Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
03 Mar 2008 BioWa Announces Expansion of License Agreement With Genetech for BioWa's POTELLIGENT(R) Technology
03 Mar 2008 Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
29 Feb 2008 Herceptin approved in Japan for early treatment in patients with HER2-positive breast cancer
27 Feb 2008 MorphoSys and Sigma-Aldrich Enter into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
27 Feb 2008 FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
26 Feb 2008 Bradmer announces phase ii results published in newly diagnosed Glioblastoma which demonstrate improved survival and support upcoming Phase III study
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 151 - 200 of 1043

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Thrombopoiesis-Stimulating Agents (TPO)

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics